Literature DB >> 19305958

[Drug therapy during pregnancy].

C Schaefer1, C Weber-Schoendorfer.   

Abstract

Most acute and chronic diseases do not require termination of a pregnancy nor is a pregnancy a reason to withhold necessary drug therapy. As many pregnancies are unplanned, any drug treatment during reproductive age should consider the occurrence of a pregnancy. Wherever possible, only medicinal drugs with sufficient documentation in pregnant women not indicating developmental toxicity should be chosen. There are acceptable drugs for the majority of diseases, although many of them are labeled as contraindicated during pregnancy. This article provides an overview on prenatal risks of ACE-inhibitors, AT II-receptor antagonists, antiepileptics, SSRI, atypical neuroleptics, lithium, coumarin anticoagulants, retinoids, selected antibiotics, immunomodulatory drugs and provides treatment recommendations for the most common diseases.

Entities:  

Mesh:

Year:  2009        PMID: 19305958     DOI: 10.1007/s00108-009-2332-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  16 in total

1.  Teratogen update: azathioprine and 6-mercaptopurine.

Authors:  Janine E Polifka; J M Friedman
Journal:  Teratology       Date:  2002-05

Review 2.  Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis.

Authors:  Dieneke van Driel; Judit Wesseling; Pieter J J Sauer; Bert C L Touwen; Eveline van der Veer; Hugo S A Heymans
Journal:  Teratology       Date:  2002-09

3.  Fetal malformations associated with mycophenolate mofetil for lupus nephritis.

Authors:  Ziad El Sebaaly; Bernard Charpentier; Renaud Snanoudj
Journal:  Nephrol Dial Transplant       Date:  2007-05-03       Impact factor: 5.992

4.  Trastuzumb exposure during pregnancy.

Authors:  Corinna Weber-Schoendorfer; Christof Schaefer
Journal:  Reprod Toxicol       Date:  2008-02-29       Impact factor: 3.143

5.  Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study.

Authors:  Christof Schaefer; Doreen Hannemann; Reinhard Meister; Elisabeth Eléfant; Wolfgang Paulus; Thierry Vial; Minke Reuvers; Elisabeth Robert-Gnansia; Judy Arnon; Marco De Santis; Maurizio Clementi; Elvira Rodriguez-Pinilla; Alla Dolivo; Paul Merlob
Journal:  Thromb Haemost       Date:  2006-06       Impact factor: 5.249

Review 6.  Low dose weekly methotrexate in early pregnancy. A case series and review of the literature.

Authors:  M Ostensen; H Hartmann; K Salvesen
Journal:  J Rheumatol       Date:  2000-08       Impact factor: 4.666

7.  Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.

Authors:  Jeffry A Katz; Christian Antoni; Gregory F Keenan; Deirdre E Smith; Stephen J Jacobs; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

8.  Cyclophosphamide, methotrexate, and cytarabine embropathy: is apoptosis the common pathway?

Authors:  Keith K Vaux; Nathanial C O Kahole; Kenneth Lyons Jones
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2003-06

9.  A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database.

Authors:  John D Carter; Anil Ladhani; Louis R Ricca; Joanne Valeriano; Frank B Vasey
Journal:  J Rheumatol       Date:  2009-03       Impact factor: 4.666

10.  Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.

Authors:  Orna Diav-Citrin; Svetlana Shechtman; Dafna Weinbaum; Rebecka Wajnberg; Meytal Avgil; Elena Di Gianantonio; Maurizio Clementi; Corinna Weber-Schoendorfer; Christof Schaefer; Asher Ornoy
Journal:  Br J Clin Pharmacol       Date:  2008-07-11       Impact factor: 4.335

View more
  2 in total

1.  Cardiοvascular diseases in pregnancy.

Authors:  Dimitrios Godosis; Spyridon Komaitis; Konstantinos Tziomalos; Maria Baltatzi; Georgios Ntaios; Christos G Savopoulos; Apostolos I Hatzitolios
Journal:  Am J Cardiovasc Dis       Date:  2012-05-15

Review 2.  [Pregnancy and inflammatory bowel disease].

Authors:  J Walldorf; K Zwirnmann; T Seufferlein
Journal:  Internist (Berl)       Date:  2011-01       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.